timothy sykes logo
Moderna Falls 3% Despite Morgan Stanley Target Increase Thumbnail

Moderna Falls 3% Despite Morgan Stanley Target Increase

TIMOTHY SYKES•UPDATED NOV. 17, 2026, 9:35 AM ET

Moderna fell 3% as Morgan Stanley raised its target but kept a neutral rating while awaiting more cancer-trial evidence.

MRNA Candlestick Chart

Why Moderna Stock Is Falling Today

Moderna fell 3% after Morgan Stanley, an investment bank, kept a neutral rating despite raising its price target. Shares last traded at $209.85 in trading after the market closed, compared with the prior close of $215.27. The improved outlook for its cancer treatment did not translate into a stronger stock recommendation.

Moderna Intismeran Melanoma Trial Results

Moderna’s experimental cancer treatment Intismeran is tailored to markers in each patient’s tumor to help the immune system recognize cancer. Its melanoma study tested treatment after surgery to reduce the chance of this serious skin cancer returning. Morgan Stanley said the findings showed the approach works in a late-stage trial, the final major test before regulators consider approval.

Moderna Morgan Stanley Price Target Increase

Morgan Stanley raised its price target to $200 from $95, leaving it below the latest share price. It kept Equalweight, a neutral recommendation compared with the stocks it tracks, while awaiting kidney-cancer evidence. The higher target comes after Moderna’s earlier melanoma presentation and reflects a larger estimated sales opportunity.

Moderna Opening Bounce Meets Sellers

The opening change was +2.13%, and shares reached a high near $220 this morning before sellers met the bounce. Moderna had a daily move this large as recently as the prior session, so today’s swing is not unusually large for this stock.

Quick Financial Overview

Moderna is a large-cap, a business valued at $84.91B, with real sales and a quarterly profit. It held $5.17B in cash, cash equivalents, and short-term investments as of September 30, 2026. That would cover about ten months if its latest quarterly rate of cash use continued.

Moderna Revenue and Cash Use

Quarterly revenue was $1.31B, with net income of $162.0M. Yet operations used $1.56B in cash during the same period. Reported profit and cash flow measure different things, so earnings alone do not show how much money remains to fund development.

Moderna Stock Pullback Interrupts Its Longer Rally

Moderna has retreated from the $250 level over the past five sessions, interrupting a longer rally that left shares up 352% over six months. Today’s failed bounce shows that buyers have not yet reversed the recent selling.

Trading Perspective

Reclaiming the $220 level, the bottom of today’s opening gap, would be a recovery test because shares already trade below it. Beyond that, the $280 level remains the longer-term ceiling where buyers previously ran out of strength. A bounce that stalls below the gap would leave the recent decline intact.


Moderna Kidney Cancer Trial Next Step

The kidney-cancer study is a mid-stage trial, which tests whether treatment works while continuing to assess safety. Its next checkpoint is an interim analysis, a planned look at results before the study ends.

Conclusion

Morgan Stanley expects the early kidney-cancer results late this year or early next year. Success would support use beyond melanoma; a weak result would limit that case without undoing the skin-cancer findings. The existing cash cushion supports the wait if spending continues at the recent rate.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:


How much has this post helped you?



Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”